Edwards Lifesciences price target raised to $105 from $101 at Truist

Truist analyst Richard Newitter raised the firm’s price target on Edwards Lifesciences to $105 from $101 and keeps a Buy rating on the shares. With easier U.S. and worldwide comps in Q2 vs. Q1 and the firm’s survey work suggesting a sequential acceleration in cardiac surgery trends in the U.S., Truist sees a good possibility that y/y worlwide TAVR growth will accelerate from Q1, the analyst tells investors in a research note.